ArticleJournal of orthopaedic case reports2026
Extensive Giant Cell Tumor Involving Entire Tibia with Talar Extension and Pulmonary Metastases: Successful Limb Preservation with Denosumab and Angioembolization.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Giant cell tumor of bone (GCTB) is a benign but locally aggressive neoplasm with a recognized propensity for recurrence and occasional pulmonary metastasis. Diffuse involvement of an entire long bone is exceptionally rare. Case Report: A 29-year-old female with four previous surgeries for recurrent distal tibial giant cell tumor presented with extensive involvement of the entire tibia, talar extension, and pulmonary metastases. Histopathology and H3.3G34W immunostaining confirmed the diagnosis. Limb salvage reconstruction was not feasible and amputation was declined. Selective angioembolization followed by denosumab 120 mg monthly for 6 months resulted in significant clinical improvement and disease stabilization. At 24 months, the patient remained independently ambulatory with stable local and pulmonary disease. Conclusion: Combined angioembolization and denosumab may provide durable disease control and limb preservation in selected patients with extensive unresectable GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.